Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Reyataz

REYATAZ 200 mg hard capsules REYATAZ 300 mg hard capsules · Abschnitt 4.5 · PDF-Seite 18–19

HOS-112101 · Präparat HOS-093615

18 Medicinal products by Interaction Recommendations concerning co- therapeutic area administration ANTINEOPLASTICS AND IMMUNOSUPRESSANTS Antineoplastics Apalutamide The mechanism of interaction is CYP3A4 Co-administration with REYATAZ induction by apalutamide and CYP3A4 (with or without ritonavir) is inhibition by atazanavir/ritonavir. contraindicated due to the potential for decreased atazanavir and ritonavir plasma concentration with subsequent loss of virologic response and possible resistance to the class of protease inhibitors (see section 4.3). In addition, serum concentrations of apalutamide may be increased when coadministered with atazanavir/ritonavir, resulting in the potential for serious adverse events including seizure. Encorafenib The mechanism of interaction is CYP3A4 Co-administration of encorafenib inhibition by atazanavir and/or ritonavir. with REYATAZ (with or without ritonavir) is contraindicated due to the potential for loss of virologic response, development of resistance, increase in encorafenib plasma concentration and subsequent risk of serious adverse events such as QT interval prolongation (see section 4.3). Ivosidenib The mechanism of interaction is CYP3A4 Co-administration of ivosidenib inhibition by atazanavir and/or ritonavir. with REYATAZ (with or without ritonavir) is contraindicated due to potential for loss of virologic response, development of resistance, increase in ivosidenib plasma concentration and subsequent risk of serious adverse events such as QT interval prolongation (see section 4.3). Irinotecan Atazanavir inhibits UGT and may interfere If REYATAZ is co-administered with the metabolism of irinotecan, with irinotecan, patients should be resulting in increased irinotecan toxicities. closely monitored for adverse events related to irinotecan. Immunosuppressants Cyclosporin Concentrations of these More frequent therapeutic Tacrolimus immunosuppressants may be increased concentration monitoring of these Sirolimus when co-administered with REYATAZ medicinal products is recommended due to CYP3A4 inhibition. until plasma levels have been stabilised. CARDIOVASCULAR AGENTS Antiarrhythmics Amiodarone, Concentrations of these antiarrhythmics Caution is warranted and Systemic lidocaine, may be increased when co-administered therapeutic concentration Quinidine with REYATAZ. The mechanism of monitoring is recommended when amiodarone or systemic available. The concomitant use of lidocaine/atazanavir interaction is CYP3A quinidine is contraindicated inhibition. Quinidine has a narrow (see section 4.3). therapeutic window and is contraindicated due to potential inhibition of CYP3A by REYATAZ.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): protease (HOS-085623) lidocaine (HOS-108866) apalutamide (HOS-086212) quinidine (HOS-085593) encorafenib (HOS-086222) tacrolimus (HOS-085202) ivosidenib (HOS-112046) sirolimus (HOS-085172) ritonavir (HOS-084521) amiodarone (HOS-085596) irinotecan (HOS-112102)